Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

49993 items
12:00 AM, Mar 28, 2000  |  BC Extra | Clinical News

Regeneron begins Phase II

REGN began a Phase II trial of its Axokine second generation ciliary neurotrophic factor ( CNTF) to treat obesity and associated complications such as Type II diabetes. The double-blind, dose-ranging study will be conducted in...
12:00 AM, Mar 28, 2000  |  BC Extra | Clinical News

Aronex starts Phase II with Annamycin

ARNX started a U.S. Phase II open label trial to assess safety and efficacy of Annamycin, a liposomal anthracycline, to treat refractory breast cancer in patients overexpressing P-glycoprotein in tumor cells. ARNX was up $1.063...
12:00 AM, Mar 28, 2000  |  BC Extra | Clinical News

Enzo completes Phase I EHT899 trial

ENZ said its EHT899 oral hepatitis B virus (HBV) antigens showed no significant side effects and had improvement in disease symptoms in a 15-patient Israeli trial to treat chronic HBV infection....
12:00 AM, Mar 28, 2000  |  BC Extra | Clinical News

Avax starts Phase II cancer trial

AVXT started a U.S. Phase II study of M-Vax, its autologous therapeutic cancer vaccine, to treat patients with stage IV melanoma who have measurable disease limited primarily to lung metastases....
12:00 AM, Mar 28, 2000  |  BC Extra | Financial News

TranXenoGen raises $1.5 million

TranXenoGen (Shrewsbury, Mass.) raised $1.5 million from existing private investors and institutional funds including WestLB Panmure. The company is applying its transgenic and cloning technology to manufacture products and to create genetically modified animals for...
12:00 AM, Mar 28, 2000  |  BC Extra | Financial News

Cytogen files for follow-on

Proteomics and oncology play CYTO filed to sell 6 million shares, with a 900,000-share overallotment. The follow-on will be underwritten by Warburg Dillon Read and CIBC World Markets. CYTO was down $0.297 to $8.813 on...
12:00 AM, Mar 28, 2000  |  BC Extra | Financial News

A soft reception

In contrast to their older siblings from the class of 2000, the most recently completed biotech IPOs are not getting very far off the ground. Shares of small molecule cancer therapeutic company Allos (ALTH) were...
12:00 AM, Mar 28, 2000  |  BC Extra | Financial News

Arqule files follow-on

ARQL filed to sell 2.5 million shares in a follow-on with a 375,000-share overallotment. The underwriters include Warburg Dillon Read; Chase H&Q; and CIBC World Markets. ARQL was down $0.813 to $19.375 on Tuesday....
12:00 AM, Mar 27, 2000  |  BC Extra | Company News

ICAgen and Yamanouchi in CNS development

ICAgen ( Research Triangle Park, N.C.) will use its ion channel modulating technology in one ion channel gene family to develop products to treat central nervous system disorders. Yamanouchi will pay upfront fees, milestones, research...
12:00 AM, Mar 27, 2000  |  BC Extra | Company News

Incara notice of allowance

INCR announced it had received notice of allowance for a U.S. patent covering an isolated hepatocyte precursor. The company expects to begin clinical testing next year of the cells as an intravenous treatment for liver...

Pages